Regeneron Pharmaceuticals is a biotechnology business based in the US. Regeneron Pharmaceuticals stocks (REGN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $657.15 – an increase of 1.8% over the previous week. Regeneron Pharmaceuticals employs 10,368 staff and has a trailing 12-month revenue of around $16.1 billion.
How to buy stocks in Regeneron Pharmaceuticals
- Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – REGN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- Can I buy shares in Regeneron Pharmaceuticals?
- Has coronavirus impacted Regeneron Pharmaceuticals shares?
- Regeneron Pharmaceuticals shares summary
- Compare share dealing platforms
- Is Regeneron Pharmaceuticals stock a buy or sell?
- Regeneron Pharmaceuticals performance over time
- Is Regeneron Pharmaceuticals suitable for ethical investing?
- Are Regeneron Pharmaceuticals shares over-valued?
- Regeneron Pharmaceuticals's financials
- How volatile are Regeneron Pharmaceuticals shares?
- Does Regeneron Pharmaceuticals pay a dividend?
- Other common questions
Regeneron Pharmaceuticals stock price (NASDAQ:REGN)Use our graph to track the performance of REGN stocks over time.
Regeneron Pharmaceuticals shares at a glance
|Latest market close||$657.15|
|52-week range||$492.13 - $747.42|
|50-day moving average||$674.91|
|200-day moving average||$635.44|
|Wall St. target price||$702.05|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$71.97|
Compare stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Regeneron Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Regeneron Pharmaceuticals price performance over time
|1 week (2022-05-11)||7.19%|
|1 month (2022-04-20)||-8.68%|
|3 months (2022-02-18)||6.83%|
|6 months (2021-11-19)||0.68%|
|1 year (2021-05-21)||29.69%|
|2 years (2020-05-21)||17.14%|
|3 years (2019-05-21)||112.02%|
|5 years (2017-05-19)||46.03%|
Is Regeneron Pharmaceuticals under- or over-valued?
Valuing Regeneron Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Regeneron Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Regeneron Pharmaceuticals's P/E ratio
Regeneron Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Regeneron Pharmaceuticals shares trade at around 9x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Regeneron Pharmaceuticals's PEG ratio
Regeneron Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.6932. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Regeneron Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Regeneron Pharmaceuticals's EBITDA
Regeneron Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $9.2 billion.
The EBITDA is a measure of a Regeneron Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Regeneron Pharmaceuticals financials
|Revenue TTM||$16.1 billion|
|Operating margin TTM||55.67%|
|Gross profit TTM||$10.7 billion|
|Return on assets TTM||26.25%|
|Return on equity TTM||54.21%|
|Market capitalisation||$70.9 billion|
TTM: trailing 12 months
Regeneron Pharmaceuticals's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Regeneron Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Regeneron Pharmaceuticals's total ESG risk score
Total ESG risk: 22.33
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Regeneron Pharmaceuticals's overall score of 22.33 (as at 01/01/2019) is pretty good – landing it in it in the 27th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Regeneron Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Regeneron Pharmaceuticals's environmental score
Environmental score: 1.51/100
Regeneron Pharmaceuticals's environmental score of 1.51 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Regeneron Pharmaceuticals's social score
Social score: 13.94/100
Regeneron Pharmaceuticals's social score of 13.94 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Regeneron Pharmaceuticals's governance score
Governance score: 5.88/100
Regeneron Pharmaceuticals's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Regeneron Pharmaceuticals's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Regeneron Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Regeneron Pharmaceuticals has, for the most part, managed to keep its nose clean.
Regeneron Pharmaceuticals share dividends
We're not expecting Regeneron Pharmaceuticals to pay a dividend over the next 12 months.
Regeneron Pharmaceuticals share price volatility
Over the last 12 months, Regeneron Pharmaceuticals's shares have ranged in value from as little as $492.13 up to $747.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regeneron Pharmaceuticals's is 0.2093. This would suggest that Regeneron Pharmaceuticals's shares are less volatile than average (for this exchange).
Regeneron Pharmaceuticals overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd. ; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.
Stocks similar to Regeneron Pharmaceuticals
Regeneron Pharmaceuticals in the news
Sanofi Receives Another Approval for Blockbuster Drug Dupixent
Sanofi's Dupixent wins U.S. approval for bigger use
FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More on investing
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.Read more…
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.Read more…
Here’s what you need to know about investing in the propane industry, including 3 popular propane stocks to watch.Read more…
More guides on Finder
Online gaming stocks
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of online gaming stocks.
How to buy Entain stock in Canada
Steps to owning and managing ENT stock, with 24-hour and historical pricing before you buy.
How to buy Kambi Group stock in Canada
Steps to owning and managing KAMBI stock, with 24-hour and historical pricing before you buy.
Best brokerage signup bonuses in 2022
Enjoy perks like free trades and cash rewards when you open a stock trading account with these online brokers.
How to buy Rush Street Interactive stock in Canada
Steps to owning and managing RSI stock, with 24-hour and historical pricing before you buy.
How to buy PointsBet stock in Canada
Steps to owning and managing PBTHF stock, with 24-hour and historical pricing before you buy.
How to buy Hanover Bancorp, Inc. (HNVR) stock in Canada when it goes public
Everything we know about the Hanover Bancorp, Inc. IPO, plus information on how to buy in.
How to buy PrimeBlock stock in Canada when it goes public
Everything we know about the PrimeBlock IPO, plus information on how to buy in.
How to buy Actelis Networks (ASNS) stock in Canada when it goes public
Everything we know about the Actelis Networks IPO, plus information on how to buy in.
How to buy ProFrac Holding Corp (PFHC) stock in Canada when it goes public
Everything we know about the ProFrac Holding Corp IPO, plus information on how to buy in.